1. Integrative Tumor Board: Recurrent Breast Cancer or New Primary?
- Author
-
Brook Stone, Bradly P Jacobs, Shelley Hwang, Jnani Chapman, Beverly Burns, Kevin Barrows, Deborah Hamolsky, Kathleen Sampel, Mindy Goldman, and Rupa Marya
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.drug_class ,medicine.medical_treatment ,Lumpectomy ,Estrogen receptor ,03 medical and health sciences ,0302 clinical medicine ,Complementary and alternative medicine ,Oncology ,Estrogen ,Biopsy ,medicine ,Methotrexate ,Progesterone Receptor Negative ,030212 general & internal medicine ,Lymph ,Radiology ,skin and connective tissue diseases ,business ,030217 neurology & neurosurgery ,Tamoxifen ,medicine.drug - Abstract
History of present illness: 1994 – Bilateral mammogram revealed bilateral benign calcifications confirmed by ultrasound. 1995 – increase in calcifications in the left breast. Excisional biopsy – 2.5 × 2 × 2 cm tumor positive for welldifferentiated intraductal and infiltrating ductal carcinoma, grade I. Borderline high S-phase. Estrogen and progesterone receptors positive. Her-2/ neu is negative. 1996 – Left axillary dissection, which revealed 1/17 positive lymph nodes. 1996 – Patient received cytoxan, methotrexate, 5-FU (6 cycles) with radiation sandwiched in between at 6,640 cGy over 36 fractions. Patient was then on tamoxifen for 5 years. Patient did well with routine physical exams, mammograms, and occasional ultrasounds until spring 2002 when a mammogram revealed a cluster of calcifications in the left breast. Left breast lumpectomy revealed an infiltrating ductal carcinoma with clear margins. Estrogen receptor positive. Progesterone receptor negative. Her-2/neu negative. Within 1 month, the patient was started on Arimidex. Whole body PET/CT scan was negative for metastatic disease. BRCA-1 and 2 = negative.
- Published
- 2003